Targeting G1–S-checkpoint-compromised cancers with cyclin A/B RxL inhibitors
RNA-seq (gene expression) · human · 21 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Topic
- Small cell lung cancerThis series is part of our curated briefing on it.
- Samples
- 21 samples: 6 conditions, mostly in duplicateGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- Targeting G1-S-checkpoint-compromised cancers with cyclin A/B RxL inhibitorsNature · 2025
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE291451_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1233782 and SRA study SRP568967. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 21 samples.
How we read this: 6 replicated groups read from 21 sample titles; they account for 21 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM8835877 DFCI393_305 DFCI393
- GSM8835878 DFCI393_316 DFCI393
- GSM8835879 DFCI393_323 DFCI393
- GSM8835880 DFCI393_331 DFCI393
- GSM8835881 DFCI393_346 DFCI393
- GSM8835882 DFCI393_309 DFCI393
- GSM8835883 DFCI393_320 DFCI393
- GSM8835884 DFCI393_321 DFCI393
- GSM8835885 DFCI393_325 DFCI393
- GSM8835886 DFCI393_334 DFCI393
- GSM8835887 DFCI393_340 DFCI393
- GSM8835888 H1048_R1 H1048
- GSM8835889 H1048_R2 H1048
- GSM8835890 H1048_05_R1 H1048_05
- GSM8835891 H1048_05_R2 H1048_05
- GSM8835892 H1048_04_R1 H1048_04
- GSM8835893 H1048_04_R2 H1048_04
- GSM8835894 H1048_14_R1 H1048_14
- GSM8835895 H1048_14_R2 H1048_14
- GSM8835896 H1048_PF_R1 H1048_PF
- GSM8835897 H1048_PF_R2 H1048_PF
- GSE279100 Differential KEAP1/NRF2-mediated signaling widens the therapeutic window of redox-targeting drugs in SCLC therapy [seq] 50 samples same disease briefing · shares targeting
- GSE269636 Efficacy of Polo-life kinase 1 inhibitors in preclinical models of small cell lung cancer 6 samples same disease briefing · shares inhibitors
- GSE272512 Targeting TREX1 induces innate immune response in drug resistant Small Cell Lung Cancer 6 samples same disease briefing · shares targeting
- GSE274293 Histologic transformation induced by EGFR tyrosine kinase inhibitors 4 samples same disease briefing · shares inhibitors
- GSE281782 Novel therapeutic strategy targeting STMN1 using chlorambucil-conjugated pyrrole-imidazole polyamide in small cell lung cancer 4 samples same disease briefing · shares targeting
- GSE259271 Therapeutic targeting ERRγ suppresses metastasis via extracellular matrix remodeling in small cell lung cancer (RNA-Seq) 3 samples same disease briefing · shares targeting
- GSE66298 A DNA Hypomethylation Signature Predicts Novel Anti-Tumor Activity of LSD1 Inhibitors in SCLC 136 samples same disease briefing · shares inhibitors
- GSE280643 Differential KEAP1/NRF2-mediated signaling widens the therapeutic window of redox-targeting drugs in SCLC therapy 74 samples same disease briefing · shares targeting
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.